Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade.

Bishu K, Ogut O, Kushwaha S, Mohammed SF, Ohtani T, Xu X, Brozovich FV, Redfield MM.

PLoS One. 2013 Dec 3;8(12):e81325. doi: 10.1371/journal.pone.0081325. eCollection 2013.

2.

Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure.

Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T.

J Hypertens Suppl. 1994 Jul;12(2):S31-5.

PMID:
7965263
3.

Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.

Kiernan MS, Gregory D, Sarnak MJ, Rossignol P, Massaro J, Kociol R, Zannad F, Konstam MA.

JACC Heart Fail. 2015 Mar;3(3):214-23. doi: 10.1016/j.jchf.2014.11.004. Erratum in: JACC Heart Fail. 2015 Jun;3(6):510-1.

PMID:
25742759
4.

Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor.

Regitz-Zagrosek V, Neuss M, Holzmeister J, Fleck E.

J Hypertens Suppl. 1995 Jul;13(1):S63-71.

PMID:
18800459
5.
6.

Renin-angiotensin system inhibition on noradrenergic nerve terminal function in pacing-induced heart failure.

Kawai H, Stevens SY, Liang CS.

Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H3012-9.

7.

Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.

Krum H, Shi H, Pitt B, McMurray J, Swedberg K, van Veldhuisen DJ, Vincent J, Pocock S, Zannad F; EMPHASIS-HF Study Group.

Circ Heart Fail. 2013 Jul;6(4):711-8. doi: 10.1161/CIRCHEARTFAILURE.112.000173. Epub 2013 Apr 26.

8.

Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.

Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, Iwao H.

Circulation. 2001 Jan 2;103(1):148-54.

9.

Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial.

Maejima Y, Nobori K, Ono Y, Adachi S, Suzuki J, Hirao K, Isobe M, Ito H; Heart Failure by Coadministration of Statin and Angiotensin-II Receptor Blocker (HF-COSTAR) Trial Investigators.

Circ J. 2011;75(3):589-95. Epub 2011 Jan 14.

10.

Variable phenotype in murine transverse aortic constriction.

Mohammed SF, Storlie JR, Oehler EA, Bowen LA, Korinek J, Lam CS, Simari RD, Burnett JC Jr, Redfield MM.

Cardiovasc Pathol. 2012 May-Jun;21(3):188-98. doi: 10.1016/j.carpath.2011.05.002. Epub 2011 Jul 18.

11.
12.

Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.

Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN; A-HeFT Investigators.

Am J Cardiovasc Drugs. 2007;7(5):373-80.

PMID:
18041162
13.

Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure.

Yoshida H, Takahashi M, Tanonaka K, Maki T, Nasa Y, Takeo S.

Br J Pharmacol. 2001 Sep;134(1):150-60.

14.

Simultaneous adrenal and cardiac g-protein-coupled receptor-gβγ inhibition halts heart failure progression.

Kamal FA, Mickelsen DM, Wegman KM, Travers JG, Moalem J, Hammes SR, Smrcka AV, Blaxall BC.

J Am Coll Cardiol. 2014 Jun 17;63(23):2549-57. doi: 10.1016/j.jacc.2014.02.587. Epub 2014 Apr 2.

15.

Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure.

Mulder P, Richard V, Bouchart F, Derumeaux G, Münter K, Thuillez C.

Cardiovasc Res. 1998 Sep;39(3):600-8.

16.

The renin-angiotensin system and experimental heart failure.

Wollert KC, Drexler H.

Cardiovasc Res. 1999 Sep;43(4):838-49. Review.

17.

Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice.

Zou Y, Lin L, Ye Y, Wei J, Zhou N, Liang Y, Gong H, Li L, Wu J, Li Y, Jia Z, Wu Y, Zhou J, Ge J.

J Cardiovasc Pharmacol. 2012 Mar;59(3):268-80. doi: 10.1097/FJC.0b013e31823f888f.

PMID:
22075750
18.

Essential role of sympathetic endothelin A receptors for adverse cardiac remodeling.

Lehmann LH, Rostosky JS, Buss SJ, Kreusser MM, Krebs J, Mier W, Enseleit F, Spiger K, Hardt SE, Wieland T, Haass M, Lüscher TF, Schneider MD, Parlato R, Gröne HJ, Haberkorn U, Yanagisawa M, Katus HA, Backs J.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13499-504. doi: 10.1073/pnas.1409026111. Epub 2014 Sep 2.

19.

Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.

Cavasin MA, Yang XP, Liu YH, Mehta D, Karumanchi R, Bulagannawar M, Carretero OA.

J Cardiovasc Pharmacol. 2000 Oct;36(4):472-80.

PMID:
11026648
Items per page

Supplemental Content

Write to the Help Desk